Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Ratain

Showing results (1-10 of 366) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Flushing oral oncology drugs down the toiletMark J Ratain
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
Current dilemmas in carboplatin dosingMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
From bedside to bench to bedside to clinical practice: an odyssey with irinotecanMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase II oncology trials: let's be positiveMark J Ratain
Nature Reviews. Clinical Oncology|September 10, 2014
Redefining the primary objective of phase I oncology trialsMark J Ratain
JCO Precision Oncology|January 7, 2022
Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical PharmacologistMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
The Role of Early-Phase Design-LetterMark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patientMark J Ratain
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Finding the right doseMark J Ratain
Pageof 37

Showing results (1-10 of 366) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Flushing oral oncology drugs down the toiletMark J Ratain
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
Current dilemmas in carboplatin dosingMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
From bedside to bench to bedside to clinical practice: an odyssey with irinotecanMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase II oncology trials: let's be positiveMark J Ratain
Nature Reviews. Clinical Oncology|September 10, 2014
Redefining the primary objective of phase I oncology trialsMark J Ratain
JCO Precision Oncology|January 7, 2022
Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical PharmacologistMark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
The Role of Early-Phase Design-LetterMark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patientMark J Ratain
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Finding the right doseMark J Ratain
Pageof 37